Tissue Regenix Group PLC DermaPure® Medicare coverage in further 10 States (6258I)
September 01 2016 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 6258I
Tissue Regenix Group PLC
01 September 2016
Tissue Regenix Group plc
DermaPure(R) Medicare coverage in further 10 States
Leeds, 1(st) September 2016 - Tissue Regenix Group (AIM:TRX)
("Tissue Regenix" or "The Group") the regenerative medical devices
company announces that effective from today it has gained Medicare
coverage in an additional 10 States covered by Medicare
jurisdiction National Government Services (NGS) for the use of
DermaPure(R).
NGS, whose jurisdiction covers Connecticut, Illinois, Maine,
Massachusetts, Minnesota, New Hampshire, New York, Rhode Island,
Vermont and Wisconsin, has taken the decision to retire their local
coverage determination (LCD) for cellular and tissue based products
allowing for DermaPure(R) to be eligible for Medicare reimbursement
in outpatient settings across these states. This new coverage adds
an additional 7.5 million Medicare beneficiaries and means that
Tissue Regenix has now secured Medicare reimbursement in 47 States,
totalling 93% of traditional Medicare beneficiaries.
DermaPure(R) utilises Tissue Regenix's patented dCELL(R)
Technology allowing for a regenerative approach to wound healing
and has multiple applications in the treatment of chronic and acute
wounds such as diabetic foot ulcers, venous leg ulcers, surgical
and trauma wounds.
Patti Gary, VP Clinical Affairs Tissue Regenix Wound Care, Inc.
said "We welcome the decision by NGS to retire their LCD allowing
for the use of clinically advanced and novel wound care products,
which will ultimately benefit the treatment and recovery of
patients. We are delighted that DermaPure(R) now has Medicare
coverage in 47 States allowing physicians to access and employ our
unique dCELL(R) Technology which has the potential to offer
superior clinical and economic outcomes."
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Corporate Communications 430 3073
Officer
========================================== ===========
Jefferies International Ltd Tel: 020
Simon Hardy / Harry Nicholas 7029 8000
========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
REAEANPFDELKEFF
(END) Dow Jones Newswires
September 01, 2016 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024